Improvement in aspects like forming cross-sectional imaging measurement criteria and cross-sectional MRI sequence standardization, besides the cross-sectional value of the Ki-67 scoring system, will be important characteristics for reproducibility to be enhanced. Generalizing the models with other sets of biomarkers, that is, genomic and/or transcriptomic, could potentially provide better estimates of tumor response. The utility of dynamic changes in Ki-67 and MRI features may be investigated across other NAC stages to derive additional information regarding treatment outcomes. The gene discussed is MKI67; the disease is neoplasm.